Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Annals of Oncology - Tập 34 - Trang 173-185 - 2023
H. Borghaei1, T.-E. Ciuleanu2,3, J.-S. Lee4, A. Pluzanski5, R. Bernabe Caro6, M. Gutierrez7, Y. Ohe8, M. Nishio9, J. Goldman10, N. Ready11, D.R. Spigel12, S.S. Ramalingam13, L.G. Paz-Ares14, J.F. Gainor15, S. Ahmed16, M. Reck17, M. Maio18, K.J. O’Byrne19, A. Memaj20, F. Nathan21
1Hematology and Oncology Department, Fox Chase Cancer Center, Philadelphia, USA
2Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca
3Department of Medical Oncology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
4Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
5Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
6Medical Oncology Department, Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain
7John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
8Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
9Department of Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
10David Geffen School of Medicine, UCLA, Los Angeles
11Department of Medicine, Duke University School of Medicine, Durham
12Thoracic Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology PLCC, Nashville
13Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA
14Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
15Department of Medicine, Massachusetts General Hospital, Boston, USA
16Department of Medical Oncology, University Hospitals of Leicester, Leicester, UK
17Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany
18Center for Immuno-Oncology, University Hospital of Siena and University of Siena, Siena, Italy
19Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia
20Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton
21OneClinical, Bristol Myers Squibb, Princeton

Tài liệu tham khảo

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774

Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005

Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer, N Engl J Med, 379, 2040, 10.1056/NEJMoa1810865

Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial, Lancet, 393, 1819, 10.1016/S0140-6736(18)32409-7

Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N Engl J Med, 378, 2288, 10.1056/NEJMoa1716948

West, 2019, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 20, 924, 10.1016/S1470-2045(19)30167-6

Spigel D, de Marinis F, Giaccone G, et al. IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (TX) in PD-L1-selected NSCLC. Presented at European Society for Medical Oncology (ESMO) Congress. September 27-October 1, 2019. Abstract 6256.

Paz-Ares, 2021, First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial, Lancet Oncol, 22, 198, 10.1016/S1470-2045(20)30641-0

Motzer, 2019, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial, Lancet Oncol, 20, 1370, 10.1016/S1470-2045(19)30413-9

Larkin, 2019, Five-year survival with combined nivolumab and ipilimumab in advanced melanoma, N Engl J Med, 381, 1535, 10.1056/NEJMoa1910836

Hellmann, 2019, Nivolumab plus ipilimumab in advanced non-small-cell lung cancer, N Engl J Med, 381, 2020, 10.1056/NEJMoa1910231

Paz-Ares, 2022, First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 trial, J Thorac Oncol, 17, 289, 10.1016/j.jtho.2021.09.010

Planchard

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology: (NCCN Guidelines®) for Non-Small Cell Lung Cancer. Version 1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed December 10, 2021. See the NCCN guidelines® for detailed recommendations including preferred treatment options. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Planchard, 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, iv192, 10.1093/annonc/mdy275

Brahmer, 2022, Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227, J Clin Oncol, 10.1200/JCO.2022.40.17_suppl.LBA9025

Barlesi, 2019, Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: overall survival analysis of Checkmate 817, Ann Oncol, 30, xi33, 10.1093/annonc/mdz451.001

Barlesi F, Audigier-Valette C, Felip E, et al. CheckMate 817: first-line nivolumab plus ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC. Presented at World Congress on Lung Cancer. September 7-10, 2019. Abstract OA04.02.

Antonia, 2018, Long-term outcomes with first-line nivolumab plus ipilimumab in advanced NSCLC: 3-year follow-up from CheckMate 012, J Thorac Oncol, 13, S458, 10.1016/j.jtho.2018.08.558

Ready, 2019, First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers, J Clin Oncol, 37, 992, 10.1200/JCO.18.01042

Paz-Ares L, Urban L, Audigier-Valette C, et al. CheckMate 817: safety and efficacy of flat-dose nivolumab plus weight-based low-dose Ipilimumab for the first-line treatment of advanced NSCLC. Presented at World Conference on Lung Cancer. September 23-26, 2018. P1.01-79.

Hellmann, 2017, Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study, Lancet Oncol, 18, 31, 10.1016/S1470-2045(16)30624-6

Antonia, 2019, Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis, Lancet Oncol, 20, 1395, 10.1016/S1470-2045(19)30407-3

Brahmer JR, Ciuleanu TE, Schenker M, et al. Survival of responders to nivolumab + ipilimumab as first-line treatment for advanced NSCLC in CheckMate 227 Part 1. Poster presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020; December 9-12, 2020. Abstract 67P.

Hellmann, 2018, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden, N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946

Paz-Ares, 2022, Safety of first-line nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer: a pooled analysis of CheckMate 227, CheckMate 568, and CheckMate 817, J Thorac Oncol

Hodi, 2022, Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067, J Clin Oncol, 40

Motzer, 2022, Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma, Cancer, 128, 2085, 10.1002/cncr.34180

Sharma, 2020, Dissecting the mechanisms of immune checkpoint therapy, Nat Rev Immunol, 20, 75, 10.1038/s41577-020-0275-8

Wei, 2018, Fundamental mechanisms of immune checkpoint blockade therapy, Cancer Discov, 8, 1069, 10.1158/2159-8290.CD-18-0367

Reck, 2021, Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50, J Clin Oncol, 39, 2339, 10.1200/JCO.21.00174

Boyer, 2021, Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase III KEYNOTE-598 study, J Clin Oncol, 39, 2327, 10.1200/JCO.20.03579

Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1. Presented at American Society of Clinical Oncology (ASCO) Meeting. May 29-31, 2020. Abstract 9500.

Herbst, 2020, Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC, N Engl J Med, 383, 1328, 10.1056/NEJMoa1917346

Jotte, 2020, Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial, J Thorac Oncol, 15, 1351, 10.1016/j.jtho.2020.03.028

Reck, 2021, First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update, ESMO Open, 6, 100273, 10.1016/j.esmoop.2021.100273

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 34

173-185

Thông tin tác giả